Drug and Therapeutics Bulletin 1995;33:65-67; doi:10.1136/dtb.1995.33965
Copyright © 1995 by the BMJ Publishing Group Ltd.
New drugs for hyperprolactinaemia
Relevant BNF section: 6.7.1
In 1976 we heralded the introduction of bromocriptine (Parlodel - Sandoz) as "an important advance" for the treatment of patients with hyperprolactinaemia.1 Now two new drugs are available for treating hyperprolactinaemia; cabergoline (
Dostinex - Pharmacia) which the manufacturer claims offers "a significant advance in prolactin control" and quinagolide (Norprolac - Sandoz) for which the claim is of a "significant advance in the therapy of hyperprolactinaemia". Do these newer products hold real advantages?
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
- Full Text
- Full Text (PDF)
- Submit a response
- Alert me when this article is cited
- Alert me when eLetters are posted
- Alert me if a correction is posted
Services
- Email this link to a friend
- Similar articles in this journal
- Similar articles in PubMed
- Add article to my folders
- Download to citation manager
- Request Permissions
Citing Articles
Google Scholar
PubMed
Topic Collections
Bookmark with
Register for email alerts
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
Coming soon!
The DTB archive back to 1962, volume 1, issue 1 will soon be available.
